Results 211 to 220 of about 156,396 (269)

Enzymes-enhanced antibiotic therapy reduces biofilms to undetectable levels in an implant-associated infection model. [PDF]

NPJ Biofilms Microbiomes
Buzisa Mbuku R, Poilvache H, Maigret L, Vanbever R, Van Bambeke F, Cornu O.   +5 more
europepmc   +1 more source

Rifampicin-resistant tuberculosis in Nangarhar, Afghanistan: prevalence and risk factors. [PDF]

BMC Infect Dis
Salehi SA, Muangnoicharoen S, Sriboonvorakul N, Thaipadungpanit J, Dhitavat J, Silachamroon U, Chancharoenthana W.   +6 more
europepmc   +1 more source

Tuberculosis prevention in children, adolescents, and pregnant and postpartum women in South Africa. [PDF]

S Afr Fam Pract (2004)
Rabe M, Hughes JA.
europepmc   +1 more source

Immunomodulation, cytokines and antibiotics [PDF]

, 2010
Croubels, Siska, De Backer, Patrick
core  

Sustained outcomes 3 years after all-oral 9-month regimen for rifampicin-resistant TB. [PDF]

IJTLD Open
Nguyen TMP, Le THM, Merle CSC, Guglielmetti L, Nguyen NL, Dinh VL, Nguyen BH, Hoang TTT, Nguyen VN, Callens S, Decroo T.   +10 more
europepmc   +1 more source

Microbiological Characteristics and Clinical Outcomes of Periprosthetic Infections Following Oncologic Megaprosthetic Reconstruction: A Retrospective Cohort Study. [PDF]

Pathogens
Karampikas V, Goumenos S, Tsantes AG, Trikoupis IG, Gavriil P, Roustemis AG, Zikopoulos A, Petrakis V, Papadopoulos DV, Ioannou P, Savvidou O, Kontogeorgakos V, Papagelopoulos PJ.   +12 more
europepmc   +1 more source

Fluoroquinolones vs. tetracycline agents combined with rifampicin for periprosthetic joint infections: a comparative study. [PDF]

J Bone Jt Infect
Gachet B, Robineau O, Degrendel M, Bauer J, Cappeliez B, Bontemps E, Diarra A, Patoz P, Beltrand E, Senneville E, Lafon-Desmurs B.   +10 more
europepmc   +1 more source